Study to Evaluate H56:IC31 in Preventing Rate of TB Recurrence

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

831

Participants

Timeline

Start Date

January 31, 2019

Primary Completion Date

March 20, 2023

Study Completion Date

March 30, 2024

Conditions
Tuberculosis, Pulmonary
Interventions
BIOLOGICAL

H56:IC31

5ug H56/500 nmol IC31

BIOLOGICAL

Placebo

Sterile saline for injection

Trial Locations (6)

1632

The Aurum Institute: Tembisa Clinical Research Centre, Tembisa

2570

The Aurum Institute, Klerksdorp

6850

South African Tuberculosis Vaccine Initiative , Project Office, Brewelskloof Hospital , Harlem Street, Worcester, Cape Town

7530

Task Clinical Research Centre, Bellville

Unknown

University of Cape Town Lung Institute, Mowbray

NIMR Mbeya Medical Research Centre, Mbeya

All Listed Sponsors
collaborator

Statens Serum Institut

OTHER

collaborator

South African Tuberculosis Vaccine Initiative

OTHER

collaborator

University of Cape Town Lung Institute

OTHER

collaborator

TASK Applied Science

OTHER

collaborator

The Aurum Institute NPC

OTHER

collaborator

National Institute for Medical Research, Tanzania

OTHER_GOV

collaborator

Ospedale San Raffaele

OTHER

collaborator

European and Developing Countries Clinical Trials Partnership (EDCTP)

OTHER_GOV

lead

International AIDS Vaccine Initiative

NETWORK